{"id":"NCT00540449","sponsor":"Tibotec Pharmaceuticals, Ireland","briefTitle":"TMC278-TiDP6-C209: A Clinical Trial in Treatment Naive HIV-1 Patients Comparing TMC278 to Efavirenz in Combination With Tenofovir + Emtricitabine.","officialTitle":"A Phase III, Randomized, Double-blind Trial of TMC278 25 mg q.d. Versus Efavirenz 600mg q.d. in Combination With a Fixed Background Regimen Consisting of Tenofovir Disoproxil Fumarate and Emtricitabine in Antiretroviral-naive HIV-1 Infected Subjects.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-05","primaryCompletion":"2010-02","completion":"2011-12","firstPosted":"2007-10-08","resultsPosted":"2011-07-11","lastUpdate":"2016-03-29"},"enrollment":694,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["HIV Infections","HIV-1","Human Immunodeficiency Virus Type 1"],"interventions":[{"type":"DRUG","name":"TMC278","otherNames":[]},{"type":"DRUG","name":"Efavirenz","otherNames":[]}],"arms":[{"label":"Efavirenz","type":"ACTIVE_COMPARATOR"},{"label":"TMC278","type":"EXPERIMENTAL"}],"summary":"The purpose of this trial is to compare the effectiveness, safety and tolerability of TMC278 given at a dose of 25 mg once daily versus efavirenz (EFV) at a dose of 600 mg once daily, when combined with a fixed background regimen consisting of emtricitabine (FTC) + tenofovir disoproxil fumarate (TDF), in HIV-1 infected patients who have not yet taken any anti-HIV drugs. The following evaluations will be done: antiviral activity, immunologic changes, and viral geno-/phenotype evolution, relationship of Pharmacokinetics (PK) and PK/Pharmacodynamics, medical resource utilization and treatment adherence.","primaryOutcome":{"measure":"Number of Participants With Virological Response (Intent-to-Treat - Time to Loss of Virologic Response [TLOVR], <50 Copies/ml) at Week 48","timeFrame":"Week 48","effectByArm":[{"arm":"TMC278","deltaMin":287,"sd":null},{"arm":"Efavirenz","deltaMin":285,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":8},"locations":{"siteCount":92,"countries":["United States","Argentina","Australia","Austria","Brazil","Canada","Denmark","France","Mexico","Netherlands","Portugal","Puerto Rico","Romania","Russia","South Africa","Spain","Sweden","Taiwan","Thailand","United Kingdom"]},"refs":{"pmids":["23714781","22532465","21763936"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":40,"n":346},"commonTop":["Dizziness","Diarrhoea","Upper respiratory tract infection","Headache","Nasopharyngitis"]}}